Top

Published in:

01-01-2011 | Original Article

Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function

Authors: Dagmar-Christiane Fischer, Claudia Jensen, Anja Rahn, Birgit Salewski, Günther Kundt, Geert J. Behets, Patrick D’Haese, Dieter Haffner

Published in: Pediatric Nephrology | Issue 1/2011

Abstract

Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953CrossRefPubMed

Moe SM, Drueke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chron Kidney Dis 14:3–12CrossRef

Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K (2004) Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 24:25–38CrossRefPubMed

Kiela PR, Ghishan FK (2009) Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 89:7–14CrossRefPubMed

Lund RJ, Davies MR, Brown AJ, Hruska KA (2004) Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 15:359–369CrossRefPubMed

Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis–from clinical observation towards molecular understanding. Osteoporos Int 18:251–259CrossRefPubMed

Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9[Suppl 4]:3–13CrossRefPubMed

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045CrossRefPubMed

Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119[Suppl 2]:S150–S162CrossRefPubMed

10.

Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H (2005) Effect of etidronate on aortic calcification and bone metabolism in calcitoriol-treated rats with subtotal nephrectomy. J Pharmacol Sci 99:89–94CrossRefPubMed

11.

Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617–625CrossRefPubMed

12.

Neven EG, De Broe ME, D'Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580–582CrossRefPubMed

13.

Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824CrossRefPubMed

14.

Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915PubMed

15.

Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577–1583CrossRefPubMed

16.

Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537–1538CrossRefPubMed

17.

Geng Z, Monier-Faugere MC, Bauss F, Malluche HH (2000) Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 54:45–53PubMed

18.

Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S (2005) Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 5:174–181PubMed

19.

Haffner D, Hocher B, Müller D, Simon K, Konig K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U (2005) Systemic cardiovascular disease in uremic rats induced by 1, 25(OH)₂D₃. J Hypertens 23:1067–1075CrossRefPubMed

20.

Brkovic D, Seibel M, Juchem R, Linke J, Rohde D, Bauss F (2004) Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats. J Urol 171:921–925CrossRefPubMed

21.

Brkovic D, Linke J, Jakse G, Bauss F (2005) Changes in bone structure after augmentation cystoplasty in chronic uraemic rats. BJU Int 95:1066–1070CrossRefPubMed

22.

Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salome M, Cox AG, Denton J, De Broe ME, D'Haese PC (2005) Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67:1830–1836CrossRefPubMed

23.

Donath K, Breuner G (1982) A method for the study of undecalcified bones and teeth with attached soft tissues. The Säge-Schliff (sawing and grinding) technique. J Oral Pathol 11:318–326CrossRefPubMed

24.

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595–610CrossRefPubMed

25.

Hunziker EB (1994) Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc Res Tech 28:505–519CrossRefPubMed

26.

Eurell JA, Sterchi DL (1994) Microwaveable toluidine blue stain for surface staining of undecalcified bone sections. J Histotechnol 17:357–359

27.

Cruz-Orive LM, Hunziker EB (1986) Stereology for anisotropic cells: application to growth cartilage. J Microsc 143:47–80PubMed

28.

Cobo A, Lopez JM, Carbajo E, Santos F, Alvarez J, Fernandez M, Weruaga A (1999) Growth plate cartilage formation and resorption are differentially depressed in growth retarded uremic rats. J Am Soc Nephrol 10:971–979PubMed

29.

Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105CrossRefPubMed

30.

Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119CrossRefPubMed

31.

Ishitani MB, Milliner DS, Kim DY, Bohorquez HE, Heimbach JK, Sheedy PF 2nd, Morgenstern BZ, Gloor JM, Murphy JG, McBane RD, Bielak LF, Peyser PA, Stegall MD (2005) Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients. Am J Transplant 5:1689–1693CrossRefPubMed

32.

Raggi P, Giachelli C, Bellasi A (2007) Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 4:26–33CrossRefPubMed

33.

Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233CrossRefPubMed

34.

Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356–363CrossRefPubMed

35.

Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke KD, Andreae J, Haffner D, Querfeld U (2006) Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease–impact of calcium and vitamin D therapy. Nephrol Dial Transplant 21:1906–1914CrossRefPubMed

36.

Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. German study group for growth hormone treatment in chronic renal failure. N Engl J Med 343:923–930CrossRefPubMed

37.

Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F (2005) Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 20:313–318CrossRefPubMed

38.

Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627CrossRefPubMed

Title: Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function
Authors: Dagmar-Christiane Fischer
Claudia Jensen
Anja Rahn
Birgit Salewski
Günther Kundt
Geert J. Behets
Patrick D’Haese
Dieter Haffner
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 1/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-010-1660-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Measurement of saliva tacrolimus levels in pediatric renal transplant recipients

Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome

An unusual case of gross hematuria with acute renal failure: answer

Variable renal phenotype in a family with an INF2 mutation

Ambulatory blood pressure monitoring and renal functions in term small-for-gestational age children

Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection